Compare
Amgen vs BioMarin Pharmaceutical (AMGN vs BMRN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and BioMarin Pharmaceutical (BMRN) +6.1%; so far this year the figures are +40.7% and -5.7%.
Amgen is the larger company by market value, about 23.0 times the size of BioMarin Pharmaceutical.
Revenue grew +8.2% at AMGN and +18.1% at BMRN over the last year.
AMGN yields 2.16%. BMRN pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | BMRN | |
|---|---|---|
| Price | $460.42 | $56.03 |
| 1-day | +0.03% | -0.16% |
| YTD | +40.67% | -5.72% |
| 1 year | +43.94% | +6.12% |
| 3 years | +76.51% | -33.31% |
| Market cap | $249.1B | $10.8B |
| P/E | 26.7 | — |
| P/S | 6.40 | 2.97 |
| P/B | 17.35 | 1.73 |
| Revenue growth | +8.20% | +18.10% |
| EPS growth | +33.30% | -103.70% |
| Gross margin % | 70.9 | 76.0 |
| Net margin % | 24.1 | -0.5 |
| ROE % | 65.4 | -0.3 |
| Debt / equity | 3.76 | 0.67 |
| FCF yield % | 3.8 | 5.1 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.34 |
| RSI (14) | 60.5 | 45.2 |
| Technical rating |